Corticobasal Degeneration (CBD), Dementia With Lewy Bodies (DLB), Multiple System Atrophy, Progressive Supranuclear Palsy (PSP)
Conditions
Brief summary
This goal of this observational study is to clarify the variations in the natural course of atypical parkinsonian syndromes (APS, including MSA, DLB, PSP, and CBD), such as the progression rate of motor and non-motor symptoms and characteristic imaging evolution patterns. Establish a comprehensive assessment framework for APS, and develop clinical and biological databases to identify biomarkers with early predictive value.
Interventions
OTHERWe did not apply any interventions; only observational research was conducted.
We did not apply any interventions; only observational research was conducted.
Sponsors
Second Affiliated Hospital of Soochow University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. MSA : Meets the "probable MSA" criteria in the 2022 Chinese expert consensus on MSA diagnosis (MSA-P or MSA-C subtype); disease duration ≤3 years (from onset of first motor symptoms) . 2. DLB : Meets "probable DLB" criteria per the 2017 McKeith diagnostic criteria; MMSE ≥18 (to exclude severe dementia confounding assessment) . 3. PSP : Meets "probable PSP-Richardson syndrome" criteria per the 2017 PSP diagnostic standards; vertical gaze palsy or postural instability with duration ≤2 years . 4. CBD : Meets "probable CBD" criteria per the 2019 Chinese expert consensus on corticobasal degeneration diagnosis and treatment; asymmetric cortical symptoms (apraxia/dystonia/alien limb).
Exclusion criteria
1. Parkinson's disease , spinocerebellar ataxia (SCA) and other secondary autonomic failure . 2. Vascular parkinsonism , Parkinsonism caused by stroke , tumor , or immune-mediated encephalitis .
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Natural disease progression of various atypical parkinsonian syndromes | up to 36 months | To observe the differences in the natural disease progression of various atypical parkinsonian syndromes (APS, including MSA, DLB, PSP, and CBD), such as the progression rates of motor and non-motor symptoms and the patterns of imaging evolution. The preliminary study design involves a follow-up period of 3 years, with assessments of clinical phenotypes and/or biomarker changes every 6 months. |
Countries
China
Contacts
CONTACTJinru Zhang, PhD. MD.
CONTACTChunfeng Liu, PhD. MD
STUDY_CHAIRChunfeng Liu
Second Affiliated Hospital of Soochow University
Outcome results
None listed